Pancrelipase delayed-release capsules (CREON) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery: A double-blind randomized trial

David C. Whitcomb, Glen A. Lehman, Galina Vasileva, Ewa Malecka-Panas, Natalya Gubergrits, Yannan Shen, Suntje Sander-Struckmeier, Steven Caras

Research output: Contribution to journalArticle

104 Scopus citations

Abstract

Objectives: Pancreatic-enzyme replacement therapy (PERT) is the standard of care to prevent maldigestion, malnutrition, and excessive weight loss in patients with exocrine pancreatic insufficiency (EPI) due to chronic pancreatitis (CP) or pancreatic surgery (PS). Our objective was to assess the efficacy and safety of a new formulation of pancrelipase (pancreatin) delayed-release 12,000-lipase unit capsules (CREON) in patients with EPI due to CP or PS. Methods: This was a double-blind, randomized, multicountry, placebo-controlled, parallel-group trial enrolling patients 18 years old with confirmed EPI due to CP or PS conducted in clinical research centers or hospitals. After a 5-day placebo run-in period (baseline), patients were randomized to pancrelipase (72,000 lipase units per meal; 36,000 per snack) or placebo for 7 days. All patients received an individually designed diet to provide at least 100 g of fat per day. The primary efficacy measure was the change in coefficient of fat absorption (CFA) from baseline to end of the double-blind period, analyzed using non-parametric analysis of covariance. Secondary outcomes included the coefficient of nitrogen absorption (CNA), clinical symptoms, and safety parameters. Results: In total, 25 patients (median age of 54 years, 76% male) received pancrelipase and 29 patients (median age of 50 years, 69% male) received placebo. The means.d. change from baseline in CFA was significantly greater with pancrelipase vs. placebo: 32.1±18.5% vs. 8.8±12.5% (P<0.0001). Similarly, the means.±d. change from baseline in CNA was greater for pancrelipase vs. placebo: 97.78±2.3% vs. 24.4±101.0% (P=0.0013). Greater improvements from baseline in stool frequency, stool consistency, abdominal pain, and flatulence were observed with pancrelipase vs. placebo. Treatment-emergent adverse events (TEAEs) were reported in five patients (20.0%) in the pancrelipase group and in six (20.7%) in the placebo group; the most common were gastrointestinal (GI) events and metabolism/nutrition disorders. There were no treatment discontinuations due to TEAEs. Conclusions: Pancrelipase delayed-release 12,000-lipase unit capsules were effective in treating fat and nitrogen maldigestion with a TEAE rate similar to that of placebo in patients with EPI due to CP or PS.

Original languageEnglish (US)
Pages (from-to)2276-2286
Number of pages11
JournalAmerican Journal of Gastroenterology
Volume105
Issue number10
DOIs
StatePublished - Oct 2010

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Fingerprint Dive into the research topics of 'Pancrelipase delayed-release capsules (CREON) for exocrine pancreatic insufficiency due to chronic pancreatitis or pancreatic surgery: A double-blind randomized trial'. Together they form a unique fingerprint.

  • Cite this